462 related articles for article (PubMed ID: 17846394)
41. Use and reported adverse effects of new chemical entities.
Kennedy DL; Goetsch RA; Dreis MW
Am J Hosp Pharm; 1989 Mar; 46(3):558-65. PubMed ID: 2719041
[TBL] [Abstract][Full Text] [Related]
42. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
[TBL] [Abstract][Full Text] [Related]
43. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
44. Pharmacovigilance: characteristics of the most widely used drugs in Bulgaria.
Getov I; Dimitrova Z
Cent Eur J Public Health; 1999 Aug; 7(3):133-6. PubMed ID: 10499144
[TBL] [Abstract][Full Text] [Related]
45. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers.
Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345
[TBL] [Abstract][Full Text] [Related]
46. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events.
Cope JU; Morrison AE; Samuels-Reid J
Pediatrics; 2008 May; 121(5):e1133-8. PubMed ID: 18450857
[TBL] [Abstract][Full Text] [Related]
47. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Sivin I
Obstet Gynecol; 1995 Aug; 86(2):318-20. PubMed ID: 7617371
[No Abstract] [Full Text] [Related]
48. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
Chang S; Ball R; Braun MM
Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
[TBL] [Abstract][Full Text] [Related]
49. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
[TBL] [Abstract][Full Text] [Related]
50. US Food and Drug Administration: adverse event reporting.
Graham AA
CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
[TBL] [Abstract][Full Text] [Related]
51. Recognizing and reporting adverse drug reactions.
Lucas LM; Colley CA
West J Med; 1992 Feb; 156(2):172-5. PubMed ID: 1536067
[TBL] [Abstract][Full Text] [Related]
52. [Adverse events following vaccination reported to the Netherlands Pharmacovigilance Center Lareb in 2004-2006].
Labadie J; van Grootheest AC
Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2738-42. PubMed ID: 18225798
[TBL] [Abstract][Full Text] [Related]
53. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
[TBL] [Abstract][Full Text] [Related]
54. A multidisciplinary approach to adverse drug events in pediatric trauma patients in an adult trauma center.
Kalina M; Tinkoff G; Gleason W; Veneri P; Fulda G
Pediatr Emerg Care; 2009 Jul; 25(7):444-6. PubMed ID: 19564808
[TBL] [Abstract][Full Text] [Related]
55. Risk factors for self-reported adverse drug events among Medicare enrollees.
Oladimeji O; Farris KB; Urmie JG; Doucette WR
Ann Pharmacother; 2008 Jan; 42(1):53-61. PubMed ID: 18029427
[TBL] [Abstract][Full Text] [Related]
56. Surgical stapler-associated fatalities and adverse events reported to the Food and Drug Administration.
Brown SL; Woo EK
J Am Coll Surg; 2004 Sep; 199(3):374-81. PubMed ID: 15325606
[TBL] [Abstract][Full Text] [Related]
57. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
Sonawane KB; Cheng N; Hansen RA
J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
[TBL] [Abstract][Full Text] [Related]
58. Adverse event reporting for botulinum toxin type A.
Batra RS; Dover JS; Arndt KA
J Am Acad Dermatol; 2005 Dec; 53(6):1080-2. PubMed ID: 16310074
[TBL] [Abstract][Full Text] [Related]
59. An internal standard for verifying the accuracy of serious adverse event reporting: the example of an acupuncture study of 190,924 patients.
Endres HG; Molsberger A; Lungenhausen M; Trampisch HJ
Eur J Med Res; 2004 Dec; 9(12):545-51. PubMed ID: 15689300
[TBL] [Abstract][Full Text] [Related]
60. Infusion pump adverse events: experience from medical device reports.
Brown SL; Morrison AE; Parmentier CM; Woo EK; Vishnuvajjala RL
J Intraven Nurs; 1997; 20(1):41-9. PubMed ID: 9060364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
